These results suggest that the baseline MUC2 expression in benign ovarian tumors corresponds to MUC2-/+ immunostaining, whereas MUC2++/+++ immunostaining is more specific to malignant tumors and represents a genuine overexpression status [23-25]. Here, MUC2 is linked to cancer.